Sotorasib (Lumykras™). HTA ID: 21070

Assessment Status Rapid review complete
HTA ID 21070
Drug Sotorasib
Brand Lumykras®
Indication As monotherapy for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and who have progressed after at least one prior line of systemic therapy.
Assessment Process
Rapid review commissioned 20/12/2021
Rapid review completed 25/01/2022
Rapid review outcome A full HTA is not recommended until additional efficacy and/or safety data is submitted. On the basis of current evidence, the NCPE recommends that sotorasib not be considered for reimbursement*

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.